WHO Updates HIV Treatment Guidelines, Prioritizing Cost-Effectiveness and Patient Adherence
Table of Contents
The World Health Organization (WHO) has released updated recommendations for the clinical management of HIV, focusing on improved treatment outcomes, reduced mortality, and ultimately, the elimination of AIDS as a public health threat. The revised guidelines address antiretroviral therapy, prevention of vertical transmission, and combating tuberculosis (TB) among individuals living with HIV.
The new recommendations, building on guidelines published in 2021, reflect recent advancements in HIV treatment and prevention strategies. They emphasize a scientific, evidence-based approach while considering the sustainability of costs for global implementation.
The WHO continues to endorse dolutegravir-based regimens as the preferred first-line and subsequent treatment option for HIV. However, significant changes have been introduced for patients experiencing treatment failure. When a protease inhibitor (PI) is necessary, darunavir/ritonavir is now the recommended choice, superseding previous preferences for atazanavir/ritonavir or lopinavir/ritonavir.
The guidelines also support the strategic reuse of tenofovir and abacavir in subsequent treatment lines, citing improved outcomes, programmatic benefits, and potential cost savings. Recognizing challenges with daily medication adherence, the WHO now recommends long-acting injectable antiretroviral therapy for suitable adults and adolescents. Furthermore, two-drug oral regimens are suggested as simplification options for clinically stable individuals.
Strengthening Prevention of Vertical HIV Transmission
Despite progress in eliminating mother-to-child transmission, new HIV infections in infants continue to occur, particularly during breastfeeding. The updated guidelines champion a person-centered public health approach that prioritizes maternal choice and infant well-being.
The WHO maintains its recommendation for exclusive breastfeeding for the first six months, potentially extending to 12 or even 24 months or more, alongside effective maternal antiretroviral therapy and appropriate complementary feeding. All newborns exposed to HIV should receive six weeks of postnatal prophylaxis, ideally with nevirapine, with higher-risk infants receiving enhanced triple-drug prophylaxis. Prolonged neonatal prophylaxis can be considered until maternal viral suppression is achieved or breastfeeding ceases.
Prioritizing Tuberculosis Prevention in People Living with HIV
Tuberculosis remains a leading cause of death among people with HIV. To enhance prevention efforts, the WHO now recommends a three-month weekly regimen of isoniazid plus rifapentine (3HP) as the preferred preventive treatment for adults and adolescents living with HIV. Alternative regimens remain viable based on clinical and programmatic factors. Integrated interventions are crucial for streamlining service delivery and reducing TB-related mortality within this vulnerable population.
“These updated recommendations reflect WHO’s commitment to ensuring that people living with HIV benefit from the most effective, safe and practical treatment options available,” stated a senior official. “By simplifying treatment, improving adherence and closing persistent gaps in prevention, they will help countries strengthen HIV programs and save lives.”
Keep reading
